Literature DB >> 31919775

Thyroid eye disease: current and potential medical management.

Jessica M Pouso-Diz1, Jose M Abalo-Lojo2, Francisco Gonzalez3,2.   

Abstract

INTRODUCTION: Thyroid eye disease (TED) is the most frequent extra-thyroid manifestation of Graves' disease and it is more frequent in middle age and in female gender. Nowadays, the causal mechanisms of this disease are not completely understood, but the current available studies suggest that the main causative factor is the thyroid stimulating hormone receptor.
MATERIALS AND METHODS: To collect reports on TED medical management, a thorough literature search was performed in PubMed database. An additional search was made in Google Scholar to complete the collected items.
RESULTS: Among the indentified risk factors, tobacco habit is the most relevant. The main criteria to choose a suitable treatment are the activity and severity of the disease. Support measures can be used to improve the patient's symptoms in any phase of the disease. There is a large number of drugs proposed to manage TED, although with different reported rates of success.
CONCLUSIONS: Currently, the drugs of choice are corticosteroids in moderate-to-severe and in sight-threatening forms. The main problem of corticosteroids is their spectrum of side effects. Therefore, other alternatives are being suggested for medical management of this disease. The efficacy of these alternatives remains unclear.

Entities:  

Keywords:  Corticosteroids; Graves’ disease; TSHR; Thyroid eye disease

Mesh:

Substances:

Year:  2020        PMID: 31919775     DOI: 10.1007/s10792-019-01258-7

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  138 in total

1.  Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism.

Authors:  L Bartalena; C Marcocci; F Bogazzi; M Panicucci; A Lepri; A Pinchera
Journal:  N Engl J Med       Date:  1989-11-16       Impact factor: 91.245

2.  Graves' orbitopathy activation after radioactive iodine therapy with and without steroid prophylaxis.

Authors:  G Vannucchi; I Campi; D Covelli; D Dazzi; N Currò; S Simonetta; R Ratiglia; P Beck-Peccoz; M Salvi
Journal:  J Clin Endocrinol Metab       Date:  2009-06-30       Impact factor: 5.958

3.  Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy.

Authors:  George J Kahaly; Susanne Pitz; Gerhard Hommel; Manuela Dittmar
Journal:  J Clin Endocrinol Metab       Date:  2005-07-05       Impact factor: 5.958

Review 4.  Update on Graves disease: advances in treatment of mild, moderate and severe thyroid eye disease.

Authors:  Diego Strianese
Journal:  Curr Opin Ophthalmol       Date:  2017-09       Impact factor: 3.761

Review 5.  Functional and clinical aspects of the B-cell-activating factor (BAFF): a narrative review.

Authors:  G A Lied; A Berstad
Journal:  Scand J Immunol       Date:  2011-01       Impact factor: 3.487

6.  Rituximab (Rituxan) therapy for severe thyroid-associated ophthalmopathy diminishes IGF-1R(+) T cells.

Authors:  Allison N McCoy; Denise S Kim; Erin F Gillespie; Stephen J Atkins; Terry J Smith; Raymond S Douglas
Journal:  J Clin Endocrinol Metab       Date:  2014-03-26       Impact factor: 5.958

7.  Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial.

Authors:  George J Kahaly; Michaela Riedl; Jochem König; Susanne Pitz; Katharina Ponto; Tanja Diana; Elena Kampmann; Elisa Kolbe; Anja Eckstein; Lars C Moeller; Dagmar Führer; Mario Salvi; Nicola Curro; Irene Campi; Danila Covelli; Marenza Leo; Michele Marinò; Francesca Menconi; Claudio Marcocci; Luigi Bartalena; Petros Perros; Wilmar M Wiersinga
Journal:  Lancet Diabetes Endocrinol       Date:  2018-01-31       Impact factor: 32.069

8.  Euthyroid and primarily hypothyroid patients develop milder and significantly more asymmetrical Graves ophthalmopathy.

Authors:  A K Eckstein; C Lösch; D Glowacka; M Schott; K Mann; J Esser; N G Morgenthaler
Journal:  Br J Ophthalmol       Date:  2009-02-15       Impact factor: 4.638

9.  Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan.

Authors:  Takao Koike; Masayoshi Harigai; Shigeko Inokuma; Naoki Ishiguro; Junnosuke Ryu; Tsutomu Takeuchi; Syuji Takei; Yoshiya Tanaka; Yoko Sano; Hitomi Yaguramaki; Hisashi Yamanaka
Journal:  J Rheumatol       Date:  2013-11-01       Impact factor: 4.666

10.  Botulinum toxin type a for dysthyroid upper eyelid retraction.

Authors:  K E Morgenstern; J Evanchan; J A Foster; K V Cahill; J A Burns; D E E Holck; J D Perry; A E Wulc
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2004-05       Impact factor: 1.746

View more
  2 in total

1.  Mycophenolate Mofetil (CellCept®) in Combination With Low Dose Prednisolone in Moderate to Severe Graves' Orbitopathy.

Authors:  Mohammad Taher Rajabi; Seyed Mohsen Rafizadeh; Abbas Mohammadi; Bahram Eshraghi; Nader Mohammadi; Seyedeh Simindokht Hosseini; Mohammad Bagher Rajabi; Mohammad Mohsen Keshmirshekan; Mansoor Shahriari; Seyedeh Zahra Poursayed Lazarjani; Mohammad Mehdi Parandin
Journal:  Front Med (Lausanne)       Date:  2022-02-11

Review 2.  The Role of Oxidative Stress and Therapeutic Potential of Antioxidants in Graves' Ophthalmopathy.

Authors:  Tzu-Yu Hou; Shi-Bei Wu; Hui-Chuan Kau; Chieh-Chih Tsai
Journal:  Biomedicines       Date:  2021-12-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.